Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence

Pulmonary disease (PD) caused by nontuberculous mycobacteria is an emerging infection mainly in countries where the incidence of tuberculosis is in decline. It affects an elderly population, often with underlying chronic lung diseases, but its epidemiology shows significant regional variation. Guide...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Expert review of anti-infective therapy Jg. 11; H. 10; S. 1065 - 1077
Hauptverfasser: van Ingen, Jakko, Ferro, Beatriz E, Hoefsloot, Wouter, Boeree, Martin J, van Soolingen, Dick
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England Informa Healthcare 01.10.2013
Taylor & Francis
Expert Reviews Ltd
Schlagworte:
Aged
Anti-Bacterial Agents - pharmacokinetics
Anti-Bacterial Agents - therapeutic use
atypical mycobacteria
Clinical Trials as Topic
Drug Administration Schedule
Drug Dosage Calculations
Drug therapy
Evidence-Based Medicine
Human immunodeficiency virus
Humans
lung disease
Lung diseases
Medical case management
Mycobacterial infections
Mycobacterium abscessus
Mycobacterium avium
Mycobacterium avium complex
Mycobacterium chelonae
Mycobacterium fortuitum
Mycobacterium Infections, Nontuberculous - drug therapy
Mycobacterium Infections, Nontuberculous - microbiology
Mycobacterium kansasii
Mycobacterium malmoense
Mycobacterium xenopi
nontuberculous mycobacteria
Nontuberculous Mycobacteria - classification
Nontuberculous Mycobacteria - drug effects
Nontuberculous Mycobacteria - physiology
Survival Analysis
Treatment Outcome
ISSN:1478-7210, 1744-8336, 1744-8336
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Pulmonary disease (PD) caused by nontuberculous mycobacteria is an emerging infection mainly in countries where the incidence of tuberculosis is in decline. It affects an elderly population, often with underlying chronic lung diseases, but its epidemiology shows significant regional variation. Guidelines and recommendations for treatment of these infections exist, but build strongly on expert opinion, as very few good quality clinical trials have been performed in this field. Only for the most frequent causative agents, the Mycobacterium avium complex, Mycobacterium kansasii and Mycobacterium abscessus, a reasonable number of trials and case series is now available. For the less frequent causative agents of pulmonary nontuberculous mycobacterial (NTM) disease (Mycobacterium xenopi, Mycobacterium malmoense, Mycobacterium fortuitum, Mycobacterium chelonae) data is mostly limited to a few very small case series. Within this review, we have collected and combined evidence from all available trials and case series. From the data of these trials and case series, we reconstruct a more evidence-based overview of possible drug treatment regimens and their outcomes.
Bibliographie:ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Review-1
ObjectType-Article-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ObjectType-Feature-1
ISSN:1478-7210
1744-8336
1744-8336
DOI:10.1586/14787210.2013.830413